S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:SANA

Sana Biotechnology - SANA Stock Forecast, Price & News

$4.71
+0.15 (+3.29%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.44
▼
$4.76
50-Day Range
$3.19
▼
$4.99
52-Week Range
$3.15
▼
$9.60
Volume
1.01 million shs
Average Volume
970,835 shs
Market Capitalization
$898.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Sana Biotechnology MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
101.7% Upside
$9.50 Price Target
Short Interest
Bearish
32.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Sana Biotechnology in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.81) to ($1.57) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

836th out of 1,053 stocks

Biological Products, Except Diagnostic Industry

137th out of 170 stocks

See Top Rated MarketRank™ Stocks Here

SANA stock logo

About Sana Biotechnology (NASDAQ:SANA) Stock

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Receive SANA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

SANA Stock News Headlines

January 26, 2023 | msn.com
Sana Biotechnology gains FDA IND clearance for CAR T therapy for B-cell malignancies
January 26, 2023 | finance.yahoo.com
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
January 26, 2023 | benzinga.com
Morgan Stanley Maintains Overweight on Sana Biotechnology, Lowers Price Target to $13
January 26, 2023 | americanbankingnews.com
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $13.00 at Morgan Stanley
January 24, 2023 | msn.com
Morgan Stanley Maintains Overweight Rating for Sana Biotechnology: Here's What You Need To Know
January 3, 2023 | finance.yahoo.com
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022 | msn.com
Biotech industry leaders share cautious optimism for 2023 amid downturn and layoffs
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
December 11, 2022 | finance.yahoo.com
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
December 1, 2022 | msn.com
Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies
December 1, 2022 | finance.yahoo.com
Sana Biotechnology to lay off 15% of its employees
November 29, 2022 | finance.yahoo.com
Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
November 15, 2022 | finance.yahoo.com
Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category
November 4, 2022 | benzinga.com
Goldman Sachs Maintains Neutral on Sana Biotechnology, Lowers Price Target to $6
November 3, 2022 | finanznachrichten.de
Sana Biotechnology, Inc: Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates
November 3, 2022 | finance.yahoo.com
Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
November 2, 2022 | finance.yahoo.com
Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates
September 29, 2022 | msn.com
Mental health startup focused on seniors launches with $32M, backing from Arch Venture Partners
September 13, 2022 | finance.yahoo.com
Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up
September 9, 2022 | finance.yahoo.com
Sana Biotechnology to Present at September 2022 Investor Conferences
September 8, 2022 | nasdaq.com
We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully
September 3, 2022 | finance.yahoo.com
Insiders who bought in the last 12 months lose an additional US$22k as Sana Biotechnology, Inc. (NASDAQ:SANA) drops to US$1.2b
August 11, 2022 | businessinsider.com
The economy is in a downturn, and top biotech VCs are favoring startups that can bring in revenue over companies chasing cool ideas
August 4, 2022 | finance.yahoo.com
Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates
July 12, 2022 | msn.com
Spinning out science startups: UW’s Institute for Protein Design brings research beyond ivory tower
July 9, 2022 | nasdaq.com
Sana Biotechnology Inc Shares Close the Week 35.6% Higher - Weekly Wrap
See More Headlines
Receive SANA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

SANA Company Calendar

Last Earnings
11/07/2021
Today
2/01/2023
Next Earnings (Estimated)
3/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SANA
CUSIP
N/A
CIK
1770121
Web
sana.com
Phone
206-701-7914
Fax
N/A
Employees
383
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+101.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-355,930,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-58.37%
Return on Assets
-38.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.36
Quick Ratio
4.36

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.86 per share
Price / Book
1.22

Miscellaneous

Outstanding Shares
190,730,000
Free Float
123,209,000
Market Cap
$898.34 million
Optionable
Not Optionable
Beta
0.60

Key Executives

  • Dr. Steven D. Harr M.D. (Age 53)
    Pres, CEO & Director
    Comp: $1.19M
  • Dr. Richard C. Mulligan Ph.D. (Age 68)
    Exec. Vice Chairman & Head of SanaX
  • Mr. Nathan Hardy M.B.A. (Age 47)
    Exec. VP & CFO
    Comp: $683.49k
  • Dr. Sunil Agarwal M.D. (Age 53)
    Exec. VP, Head of Devel. & Chief Medical Officer
    Comp: $728.45k
  • Brittany Mccleery
    Accounting Mang.
  • Dr. Edward Rebar Ph.D. (Age 55)
    Sr. VP & CTO
  • Mr. Bernard J. Cassidy J.D. (Age 68)
    Exec. VP & Gen. Counsel
  • Ms. Robin Andrulevich (Age 57)
    Exec. VP & Chief People Officer
  • Mr. Paul Brunetta M.D.
    Sr. VP and Head of Clinical & Translational Science
  • Ms. Donna Dambach D.V.M.
    Ph.D., Sr. VP & Head of Devel. Sciences

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SANA Stock - Frequently Asked Questions

Should I buy or sell Sana Biotechnology stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SANA shares.
View SANA analyst ratings or view top-rated stocks.

What is Sana Biotechnology's stock price forecast for 2023?

2 equities research analysts have issued 1-year price targets for Sana Biotechnology's stock. Their SANA share price forecasts range from $6.00 to $13.00. On average, they expect the company's share price to reach $9.50 in the next year. This suggests a possible upside of 101.7% from the stock's current price.
View analysts price targets for SANA or view top-rated stocks among Wall Street analysts.

How have SANA shares performed in 2023?

Sana Biotechnology's stock was trading at $3.95 at the beginning of 2023. Since then, SANA shares have increased by 19.2% and is now trading at $4.71.
View the best growth stocks for 2023 here.

When is Sana Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our SANA earnings forecast.

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) posted its earnings results on Sunday, November, 7th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.03.

When did Sana Biotechnology IPO?

(SANA) raised $322 million in an initial public offering on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO.

What is Sana Biotechnology's stock symbol?

Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA."

Who are Sana Biotechnology's major shareholders?

Sana Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (5.64%), Clarius Group LLC (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christian Hordo, James J Macdonald and Patrick Y Yang.
View institutional ownership trends.

How do I buy shares of Sana Biotechnology?

Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sana Biotechnology's stock price today?

One share of SANA stock can currently be purchased for approximately $4.71.

How much money does Sana Biotechnology make?

Sana Biotechnology (NASDAQ:SANA) has a market capitalization of $898.34 million. The company earns $-355,930,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does Sana Biotechnology have?

The company employs 383 workers across the globe.

How can I contact Sana Biotechnology?

Sana Biotechnology's mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The official website for the company is sana.com. The company can be reached via phone at 206-701-7914 or via email at investor.relations@sana.com.

This page (NASDAQ:SANA) was last updated on 2/2/2023 by MarketBeat.com Staff